Paresh Rajwat has officially stepped down from his position as the Pacific Northwest head of office for Meta, where he served as vice president of product management for a decade. In his recent email to GeekWire, Rajwat described his leadership role as “an honor,” highlighting the significance of the region as Meta’s largest tech hub outside of its Menlo Park headquarters.
Rajwat expressed pride in the growth of teams and their contributions to key innovations across various sectors, including Reality Labs, Generative AI, Infrastructure, Monetization, and the Family of Apps.
As of now, Meta has not announced a successor for Rajwat, and inquiries have been made to the company for further details.
Rajwat’s Next Chapter
With a career that includes stints at industry giants like Apple, Microsoft, and Yahoo, Rajwat is now focusing on angel investing and advising startups. He expressed enthusiasm for this new phase, stating he is enjoying the opportunity to share his extensive experience with emerging entrepreneurs.
David Shoultz Joins Phase Genomics as Chief Business Officer
In related news, Seattle-based biotech startup Phase Genomics has appointed David Shoultz as its first chief business officer. Founder and CEO Ivan Liachko emphasized Shoultz’s timely expertise in accelerating the adoption of their technologies, which enable groundbreaking scientific discoveries.
Phase Genomics has been at the forefront of developing DNA sequencing technologies that can analyze complex organisms and identify chromosomal abnormalities, which are often present in tumors. Shoultz brings a wealth of experience from various health-focused organizations, including his role as co-founder and COO of Monod Bio, a spinout from the Institute for Protein Design.
Changes at Sana Biotechnology
In the biotech sector, Susan Wyrick has stepped in as the acting chief financial officer, treasurer, and principal accounting officer at Sana Biotechnology. Her appointment follows the resignation of former CFO Nathan Hardy for personal reasons. Wyrick has been with Sana for nearly six years, previously holding the role of vice president and controller at Juno Therapeutics, where she was instrumental in the company’s successful IPO.
Sana is currently engaged in developing innovative treatments for cancer, autoimmune diseases, and type 1 diabetes. The company recently celebrated the opening of a new manufacturing facility in Bothell, Washington, complementing its sites in Seattle, South San Francisco, Cambridge, Massachusetts, and Rochester, New York.
Read Also: New Venture Aims to Revolutionize Wealth Management for Ultra-High-Net-Worth Clients
